• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Strengthens Balance Sheet with Optional Early Prepayment to Reduce Term Loan by US$100 Million

    4/1/25 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email

    Early Prepayment Reduces Annual Interest Expense by US$13 Million, Extends Maturity of Term Loan to September 2027





    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated June 6, 2024 to its short form base shelf prospectus dated February 28, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an optional early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US$97.5 million. This results in interest expense savings of approximately US$13 million on an annualized basis.

    "Canopy has further improved its balance sheet with this early prepayment by reducing our overall debt position as well as lowering annual interest costs," said Judy Hong, CFO of Canopy Growth. "In addition, with this prepayment now made, we have no material debt obligation until September 2027."

    This prepayment was optional under the terms of the agreement between the Company and its senior lenders as part of a series of amendments to the Term Loan (the "Term Loan Amendment"). Pursuant to the Term Loan Amendment, Canopy Growth had the option to make this prepayment by March 31, 2025 (the "Second Prepayment"). As a result of making the Second Prepayment, the maturity date of the Term Loan has been extended to September 18, 2027.

    The optional early prepayment of the Term Loan demonstrates Canopy Growth's continued focus on reducing debt and improving its balance sheet, positioning the Company for sustainable growth in the evolving global cannabis market.

    About Canopy Growth

    Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.

    Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Tweed, 7ACRES, DOJA, Deep Space and Claybourne, as well as category-defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Germany, Poland, and Australia.

    Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA's portfolio includes ownership of Acreage Holdings, a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Brands, a leading North American edibles brand, and majority ownership of Jetty Extracts, a California-based producer of high-quality cannabis extracts and clean vape technology.

    At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer.

    For more information visit www.canopygrowth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250401949971/en/

    Alex Thomas

    Director, Communications

    [email protected] 

    Investor Contact:

    Tyler Burns

    Director, Investor Relations

    [email protected]

    Get the next $CGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

      Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a

      5/30/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Fourth Quarter and Fiscal Year 2025 Financial Results on May 30, 2025

      Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the fourth quarter and fiscal year 2025 ended March 31, 2025, before financial markets open on May 30, 2025. Following the release of its fourth quarter and fiscal year 2025 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Judy Hong, CFO on May 30, 2025, at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=1235414F-AB39-4A0B-871E-B1885B487ACD Replay Information A replay will be accessible by webcast until 11:59 PM ET on August 28, 2025 at:

      5/16/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Drives Innovation in High-Demand Segments With Latest Product Launches

      Offerings reflect a focused format strategy in Canada's adult-use market Vapes, high-THC flower, pre-roll joints, and edibles introduced across core brands Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched a series of product innovations targeting Canada's fastest-growing adult-use categories.1 The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20

      5/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care